Jalandhar Online

DelveInsight’s “Prediabetes Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Prediabetes, historical and forecasted epidemiology as well as the Prediabetes market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Prediabetes market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

To Know in detail about the Prediabetes market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Prediabetes Market Insights

Prediabetes Overview

According to the Centers for Disease Control and Prevention (CDC), prediabetes is a serious health condition where blood-sugar levels are higher than normal, but not high enough to get diagnosed easily as type 2 diabetes. Prediabetes, is also commonly referred to as borderline diabetes, which is a metabolic condition and growing global problem closely related to obesity.

Some of the key facts of the Prediabetes Market Report: 

• The Prediabetes market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• According to the CDC, prediabetes had a prevalence of 96 million among adults in the US in 2019, which accounted for 38% of the entire US adult population. Of these cases, 26.4 million people aged 65 years or older, signifying a 48.8% prevalence in that particular age group
• As per Hostalek, prediabetes progresses to type-2 diabetes in approximately 25% of subjects within 3–5 years, and as many as 70% of individuals with prediabetes will develop overt diabetes within their lifetime
• Key Prediabetes Companies: Valbiotis, Ingredia, Novo Nordisk, Advent Health, and others
• Key Prediabetes Therapies: Totum-63, Pep2Dia, Semaglutide 2.4 mg, ABA, and others
• The Prediabetes epidemiology based on gender analyzed that Prediabetes is slightly more common in males than in females

Get a Free sample for the Prediabetes Market Report –

https://www.delveinsight.com/sample-request/prediabetes-market

Key benefits of the Prediabetes Market report:

1. Prediabetes market report covers a descriptive overview and comprehensive insight of the Prediabetes Epidemiology and Prediabetes market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Prediabetes market report provides insights on the current and emerging therapies.
3. Prediabetes market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Prediabetes market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Prediabetes market.

Download the report to understand which factors are driving Prediabetes epidemiology trends @ Prediabetes Epidemiological Insights 

Prediabetes Market  

The dynamics of the Prediabetes market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.  

Prediabetes Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Prediabetes Epidemiology Segmentation:

The Prediabetes market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Prediabetes
• Prevalent Cases of Prediabetes by severity
• Gender-specific Prevalence of Prediabetes
• Diagnosed Cases of Episodic and Chronic Prediabetes

Prediabetes Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Prediabetes market or expected to get launched during the study period. The analysis covers Prediabetes market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Prediabetes Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Discover more about therapies set to grab major Prediabetes market share @ Prediabetes market forecast 

Prediabetes Therapies and Key Companies

• Totum-63: Valbiotis
• Pep2Dia: Ingredia
• Semaglutide 2.4 mg: Novo Nordisk
• ABA: AdventHealth

Prediabetes Market Drivers

• Growing Awareness among prediabetic patients, leading to increase in diagnosed patient pool
• Growth in research and developmental activities about this indication can give good returns in future

Scope of the Prediabetes Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Prediabetes Companies: Valbiotis, Ingredia, Novo Nordisk, Advent Health, and others
• Key Prediabetes Therapies: Totum-63, Pep2Dia, Semaglutide 2.4 mg, ABA, and others
• Prediabetes Therapeutic Assessment: Prediabetes current marketed and Prediabetes emerging therapies
• Prediabetes Market Dynamics: Prediabetes market drivers and Prediabetes market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Prediabetes Unmet Needs, KOL’s views, Analyst’s views, Prediabetes Market Access and Reimbursement 

Prediabetes Market Opportunities

• There is no approved treatment for Prediabetes which creates an opportunity for new players
• The current treatment options are off-label therapies for treating patients with Prediabetes, which open a platform of new therapies to boost the market of the indication

Table of Contents 

1. Prediabetes Market Report Introduction

2. Executive Summary for Prediabetes

3. SWOT analysis of Prediabetes

4. Prediabetes Patient Share (%) Overview at a Glance

5. Prediabetes Market Overview at a Glance

6. Prediabetes Disease Background and Overview

7. Prediabetes Epidemiology and Patient Population

8. Country-Specific Patient Population of Prediabetes 

9. Prediabetes Current Treatment and Medical Practices

10. Prediabetes Unmet Needs

11. Prediabetes Emerging Therapies

12. Prediabetes Market Outlook

13. Country-Wise Prediabetes Market Analysis (2019–2032)

14. Prediabetes Market Access and Reimbursement of Therapies

15. Prediabetes Market Drivers

16. Prediabetes Market Barriers

17.  Prediabetes Appendix

18. Prediabetes Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

To know more about Prediabetes treatment, visit @ Prediabetes Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting